Art Flatau, Author at Patient Empowerment Network

Olutasidenib for Relapsed or Refractory Acute Myeloid Leukemia with IDH1 Mutation

September 19, 2023

Introduction Once again a new drug that was recently FDA approved for some Acute Myeloid Leukemia (AML) patients. Olutasidenib (brand name: Rezlidhia) was approved in December 2022 for AML patients […]

Art Flatau

AML Network Manager

Art Flatau lives in Austin, Texas with his wife Gretchen. They have 2 grown children. He was diagnosed with Acute Myeloid Leukemia (AML) in 1992 at the age of 31, while still in graduate school at the University of Texas. Gretchen and Art’s kids were 2 and 4 at the time. He received chemotherapy (both induction chemotherapy and then consolidation). After graduating with a Ph.D. in computer science in December 1992. He relapsed in early 1993 and then had a bone marrow transplant (BMT), his brother was a perfect match.

Omidubicel (Expanded Cord Blood) for use in Allogeneic Transplant

June 2, 2023

Introduction Umbilical Cord Blood (UCB) has been used as a source of stem cells in allogeneic (donor) transplants since the late 1980s. When doing a transplant using bone marrow (BM) […]

Art Flatau

AML Network Manager

Art Flatau lives in Austin, Texas with his wife Gretchen. They have 2 grown children. He was diagnosed with Acute Myeloid Leukemia (AML) in 1992 at the age of 31, while still in graduate school at the University of Texas. Gretchen and Art’s kids were 2 and 4 at the time. He received chemotherapy (both induction chemotherapy and then consolidation). After graduating with a Ph.D. in computer science in December 1992. He relapsed in early 1993 and then had a bone marrow transplant (BMT), his brother was a perfect match.

Rezafungin for the Treatment of Candidemia and Invasive Candidiasis in Adults

April 26, 2023

Introduction I was the patient representative on the FDA Advisory Antimicrobial Drugs Advisory Committee (AMDAC) that met on January 24, 2023, to consider whether to recommend the approval of a […]

Art Flatau

AML Network Manager

Art Flatau lives in Austin, Texas with his wife Gretchen. They have 2 grown children. He was diagnosed with Acute Myeloid Leukemia (AML) in 1992 at the age of 31, while still in graduate school at the University of Texas. Gretchen and Art’s kids were 2 and 4 at the time. He received chemotherapy (both induction chemotherapy and then consolidation). After graduating with a Ph.D. in computer science in December 1992. He relapsed in early 1993 and then had a bone marrow transplant (BMT), his brother was a perfect match.

Quizartinib in FLT3-ITD-Positive AML

January 10, 2023

Introduction I generally think of treatments for AML as old, meaning they were around when I was diagnosed in 1992, or new ones that were developed after that. In the […]

Art Flatau

AML Network Manager

Art Flatau lives in Austin, Texas with his wife Gretchen. They have 2 grown children. He was diagnosed with Acute Myeloid Leukemia (AML) in 1992 at the age of 31, while still in graduate school at the University of Texas. Gretchen and Art’s kids were 2 and 4 at the time. He received chemotherapy (both induction chemotherapy and then consolidation). After graduating with a Ph.D. in computer science in December 1992. He relapsed in early 1993 and then had a bone marrow transplant (BMT), his brother was a perfect match.

Ivosidenib and Azacitidine for IDH1-Mutated AML

November 16, 2022

There has been another significant advance in the treatment of Acute Myeloid Leukemia (AML) at least for the small subset of patients (6-10%) who have a mutation in one of […]

Art Flatau

AML Network Manager

Art Flatau lives in Austin, Texas with his wife Gretchen. They have 2 grown children. He was diagnosed with Acute Myeloid Leukemia (AML) in 1992 at the age of 31, while still in graduate school at the University of Texas. Gretchen and Art’s kids were 2 and 4 at the time. He received chemotherapy (both induction chemotherapy and then consolidation). After graduating with a Ph.D. in computer science in December 1992. He relapsed in early 1993 and then had a bone marrow transplant (BMT), his brother was a perfect match.

Naïve T-cell Depletion in Donor Blood Stem Cell Transplant Patients

August 25, 2022

Introduction T-cell depletion is a strategy to remove T-cells from bone marrow or peripheral stem cells taken from a donor before they are given to a patient. T-cell depletion (TCD) has […]

Art Flatau

AML Network Manager

Art Flatau lives in Austin, Texas with his wife Gretchen. They have 2 grown children. He was diagnosed with Acute Myeloid Leukemia (AML) in 1992 at the age of 31, while still in graduate school at the University of Texas. Gretchen and Art’s kids were 2 and 4 at the time. He received chemotherapy (both induction chemotherapy and then consolidation). After graduating with a Ph.D. in computer science in December 1992. He relapsed in early 1993 and then had a bone marrow transplant (BMT), his brother was a perfect match.

Low Testosterone in Cancer or Transplant Survivors

May 19, 2022

I was one of the authors (out of more than 50) of a review article on male specific late effects in stem cell transplant patients [1]. The article looked at […]

Art Flatau

AML Network Manager

Art Flatau lives in Austin, Texas with his wife Gretchen. They have 2 grown children. He was diagnosed with Acute Myeloid Leukemia (AML) in 1992 at the age of 31, while still in graduate school at the University of Texas. Gretchen and Art’s kids were 2 and 4 at the time. He received chemotherapy (both induction chemotherapy and then consolidation). After graduating with a Ph.D. in computer science in December 1992. He relapsed in early 1993 and then had a bone marrow transplant (BMT), his brother was a perfect match.

Introducing Art Flatau, AML Empowerment Lead

March 29, 2022

I have decided to try my hand at writing a regular blog. I hope to write a post every month or so. This first post is something of an introduction. […]

Art Flatau

AML Network Manager

Art Flatau lives in Austin, Texas with his wife Gretchen. They have 2 grown children. He was diagnosed with Acute Myeloid Leukemia (AML) in 1992 at the age of 31, while still in graduate school at the University of Texas. Gretchen and Art’s kids were 2 and 4 at the time. He received chemotherapy (both induction chemotherapy and then consolidation). After graduating with a Ph.D. in computer science in December 1992. He relapsed in early 1993 and then had a bone marrow transplant (BMT), his brother was a perfect match.

About Art Flatau

Entries by Art Flatau

Olutasidenib for Relapsed or Refractory Acute Myeloid Leukemia with IDH1 Mutation

Omidubicel (Expanded Cord Blood) for use in Allogeneic Transplant

Rezafungin for the Treatment of Candidemia and Invasive Candidiasis in Adults

Quizartinib in FLT3-ITD-Positive AML

Ivosidenib and Azacitidine for IDH1-Mutated AML

Naïve T-cell Depletion in Donor Blood Stem Cell Transplant Patients

Low Testosterone in Cancer or Transplant Survivors

Introducing Art Flatau, AML Empowerment Lead

CONNECT WITH US